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LINX®, a novel treatment for patients with
refractory asthma complicated by
gastroesophageal reflux disease: a case
report
Narin Sriratanaviriyakul1,2,3*, Celeste Kivler4, Tamas J. Vidovszky5, Ken Y. Yoneda1,2, Nicholas J. Kenyon1,2,
Susan Murin1,2 and Samuel Louie1,2
Abstract
Background: Gastroesophageal reflux disease is one of the most common comorbidities in patients with asthma.
Gastroesophageal reflux disease can be linked to difficult-to-control asthma. Current management includes gastric
acid suppression therapy and surgical antireflux procedures. The LINX® procedure is a novel surgical treatment for
patients with gastroesophageal reflux disease refractory to medical therapy. To the best of our knowledge, we
report the first case of successful treatment of refractory asthma secondary to gastroesophageal reflux disease using
the LINX® procedure.
Case presentation: Our patient was a 22-year-old white woman who met the American Thoracic Society criteria
for refractory asthma that had remained poorly controlled for 5 years despite progressive escalation to step 6
treatment as recommended by National Institutes of Health-National Asthma Education and Prevention Program
guidelines, including high-dose oral corticosteroids, high-dose inhaled corticosteroid plus long-acting β2-agonist,
leukotriene receptor antagonist, and monthly omalizumab. Separate trials with azithromycin therapy and roflumilast
did not improve her asthma control, nor did bronchial thermoplasty help. Additional consultations with two other
university health systems left the patient with few treatment options for asthma, which included cyclophosphamide.
Instead, the patient underwent a LINX® procedure after failure of maximal medical therapy for gastroesophageal reflux
disease with the additional aim of improving asthma control. After she underwent LINX® treatment, her asthma
improved dramatically and was no longer refractory. She had normal exhaled nitric oxide levels and loss of
peripheral eosinophilia after LINX® treatment. Prednisone was discontinued without loss of asthma control. The
only immediate adverse effects due to the LINX® procedure were bloating, nausea, and vomiting.
Conclusions: LINX® is a viable alternative to the Nissen fundoplication procedure for the treatment of patients
with gastroesophageal reflux disease and poorly controlled concomitant refractory asthma.
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Background
The prevalence of gastroesophageal reflux disease (GERD)
is increased among patients with asthma. Up to 80 % of
patients with asthma report GERD symptoms [1, 2]. Re-
fractory asthma accounts for 5–10 % cases of asthma, and
control of symptoms may be unattainable because of
GERD and other comorbidities. A pathophysiological link
between the two has been suggested and studied; however,
their exact correlation to one another has not been fully
established.
The National Asthma Education and Prevention Pro-
gram (NAEPP) Expert Panel recommends that GERD
should be treated only in patients with asthma and symp-
tomatic GERD. Symptoms can be absent in more than
60 % of patients confirmed to have GERD by esophageal
manometry and 24-h esophageal pH testing [3]. The two
primary management options are long-term medical acid
suppression therapy with proton pump inhibitors (PPIs)
and/or H2 receptor antagonists, and surgical Nissen fun-
doplication [4]. The latter is recommended when maximal
medical management for GERD fails. Sphincter augmen-
tation with the LINX® Reflux Management System (Torax
Medical, Shoreview, MN, USA) is a novel alternative pro-
cedure for GERD treatment. We report our experience
with a patient whose asthma was very poorly controlled
despite high-intensity asthma treatment that included sys-
temic corticosteroid, omalizumab, and bronchial thermo-
plasty, and who benefited from LINX® treatment.
Case presentation
Our patient was a 22-year-old white woman who met
the criteria of refractory asthma as determined by an
American Thoracic Society workshop in 2000. Her asthma
remained poorly controlled despite progressive escalation
therapy as recommended in NAEPP guidelines, including
daily high-dose inhaled corticosteroids plus a long-acting
β2-agonist, a leukotriene receptor antagonist, inhaled anti-
cholinergics, and daily high-dose oral corticosteroids. Her
asthma symptoms were not controlled with additional
treatments with omalizumab, macrolide therapy, and U.S.
Food and Drug Administration off-label used of roflumi-
last. The patient completed three sessions of bronchial
thermoplasty treatment, also without benefit. She later
consulted two other university health systems, whose
clinicians agreed with her diagnosis of refractory asthma
and recommended cyclophosphamide and anti-interleukin-
13 as alternative treatments.
The patient’s physical examination was remarkable
only for wheezing during acute exacerbations. Pertinent
laboratory results, radiographic findings, and investiga-
tions at three university health systems included a pul-
monary function test with moderate obstruction and
significant bronchodilator response. Her methacholine
challenge was positive for bronchial hyperactivity. Her
complete blood count was unremarkable aside from per-
ipheral blood eosinophilia of 7.2 % or 700 cells/mm3.
Her exhaled nitric oxide was consistently elevated above
100 parts per billion (ppb), reaching a peak of 266 ppb
just before she underwent the LINX® procedure. Her
antinuclear antibody titer was 1:40. Her test results for
antineutrophil cytoplasmic antibody, anticentromere,
anti-Ro/SSA and anti-La/SSB antigen, rheumatoid factor,
and anti-cyclic citrullinated peptide antibodies were all
negative. Her α1-antitrypsin level was 150 mg/mL. Her
immunoglobulin (Ig) levels (kU/L) before omalizumab
treatment were IgE 929, IgG 857, IgM 118, and IgA 110.
Her Aspergillus precipitin results were negative, and her
radioallergosorbent test panel result was positive for per-
ennial aeroallergens. Her skin prick test results for the
Northern California aeroallergen panel were positive for
multiple trees, grasses, weeds, and cat.
High-resolution computed tomography of her chest
was remarkable for bronchial wall thickening and air
trapping without evidence of bronchiectasis or tracheo-
malacia. Her bronchoscopy result was significant for
severe, diffuse erythema throughout the lower respira-
tory tract. Her bronchoalveolar lavage specimens were
unremarkable in terms of cell counts, cytology, and cul-
tures. The results of her endobronchial biopsy of the right
lower lobe were consistent with asthma with severe airway
epithelial injury and cell loss. Her steroid pharmacokinet-
ics and pharmacodynamics were within normal limits.
The patient returned to our institution and complained
of heartburn. She had been diagnosed with GERD and
had been receiving therapy with a PPI, H2 antagonist, and
metoclopramide for 2 years. Her 24-h probe monitoring
showed severe acid exposure while in supine position. We
concluded that she did not have adequate control of her
GERD despite medical management. A surgical antireflux
procedure with options of fundoplication or the LINX®
procedure was considered. The patient underwent the
LINX® procedure. Following the procedure, her asthma
control improved dramatically. Her exhaled nitric oxide
fell from 266 ppb to 17 ppb 1 month after surgery, and
her peripheral eosinophilia returned to normal levels. Pred-
nisone was discontinued 4 months after surgery. She lost
weight, and her body mass index decreased from 36.4 kg/
m2 preoperatively to 34.6 kg/m2 at her 2-week postopera-
tive follow-up. The only immediate adverse effects she ex-
perienced due to the LINX® procedure were bloating,
nausea, and vomiting, all of which have since subsided.
Discussion
GERD is one of the most common comorbidities in pa-
tients with asthma. GERD can contribute to and worsen
asthma symptoms and asthma control. Current manage-
ment of symptomatic GERD includes acid suppression
therapy and surgical antireflux procedures. The connection
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between GERD and asthma remains controversial, but an
association seems to exist [1–3]. Asthma appears to be
exacerbated by GERD, and a significant portion of patients
report improvement of asthma symptoms following better
control of GERD. Conversely, asthma treatment such as
albuterol and even corticosteroids may worsen GERD,
purportedly by reducing lower esophageal sphincter (LES)
tone [5, 6].
GERD management can be categorized into medical
management or surgical management or both. Acid sup-
pression treatment with PPIs and/or H2 antagonists is an
effective first-line therapy in most cases, and this strategy
seems to improve respiratory symptoms and reduce the
need for asthma medication, with varying degrees of
success [7].
Pharmacological therapy fails in a significant propor-
tion of patients with asthma and GERD, even after years
of clinical trials. Despite treatment, GERD may progress
and lead to complications such as strictures and Barrett’s
esophagus [8]. It is believed that acid-inhibiting medica-
tion may reduce or neutralize the acid but that reflux
can continue because of an incompetent LES. The con-
ventional surgical approach to the latter problem is
surgical fundoplication to restore a physical barrier to
reflux. Recent literature suggests that laparoscopic fun-
doplication surgery may be more effective than medical
management for GERD, at least in the short to medium
term [9]. However, fundoplication is associated with
complications and a slight mortality risk; in addition, it
alters gastric anatomy. For these reasons, in the United
States, less than 1 % of patients with GERD undergo
Nissen fundoplication [10].
Fig. 1 The LINX® Reflux Management System. The device is composed
of a series of titanium beads, each with a magnetic core, connected
together with independent titanium wires to form a ring shape
Fig. 2 a The LINX® Reflux Management System is designed to help the lower esophageal sphincter resist opening to gastric pressures. b The LINX®
Reflux Management System is designed to expand to allow for normal swallowing
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The LINX® Reflux Management System was developed
to address the “therapy gap” between conventional med-
ical acid suppression therapy and fundoplication surgery
[4]. The aim of this procedure is to restore a physio-
logical equivalent of an LES. The device is composed of
a series of titanium beads, each with a magnetic core,
connected together with independent titanium wires to
form a ring shape (Fig. 1). It serves to prevent the back-
ward flow of stomach contents (Fig. 2). It is implanted
laparoscopically at the LES. Upon swallowing by the
patient, the device expands to let the contents pass.
Once the food passes though the LES, the device returns
to its resting state. Current evidence supports its treat-
ment effect and safety profile [11]. The most common
adverse event reported is dysphagia (43 % of patients),
which is mostly mild and self-limited. In the event of a
serious adverse event, the LINX® device is retrievable.
The LINX® device is considered magnetic resonance im-
aging (MRI)-conditional, as it is safe with MRI systems
up to 1.5 T.
The case of our patient illustrates the importance of
recognizing and managing comorbidities in patients with
difficult-to-control asthma. Our patient was referred for
surgery after her GERD was refractory to maximal med-
ical management as evidenced by 24-h pH probe testing.
The LINX® was chosen over fundoplication because there
is evidence that the LINX® minimally alters gastric anat-
omy while augmenting the LES, thereby preserving the
option of fundoplication in the future should LINX® treat-
ment fail. The improvement in our patient’s asthma symp-
toms and biomarkers achieved immediately following the
procedure suggest that GERD contributed significantly to
her poor asthma control. To our knowledge, this is the
first case of successful treatment of refractory asthma sec-
ondary to GERD with the LINX® Reflux Management
System.
Conclusions
LINX® is a viable alternative to Nissen fundoplication as
a treatment option for patients with poorly controlled
GERD who have concomitant refractory asthma.
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